ReviewMedical oncology (Northwood, London, England)2018
Contemporary treatment of metastatic renal cell carcinoma.
Review in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05882747 (The Results of Surgery for Renal Cell Carcinoma Metastases in the Pancreas), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Results of Surgery for Renal Cell Carcinoma Metastases in the Pancreas
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a risk-stratified systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging.Journal of healthcare engineering · 2022Trial
- Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment.Clinical epigenetics · 2026Review
- Elevated preoperative inflammatory ratios (NLR/PLR) predict adverse pathology and poor surgical outcomes in metastatic renal cell carcinoma: a retrospective analysis.American journal of translational research · 2026Article
- NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.Frontiers in immunology · 2026Article
- Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma.Advances in radiation oncology · 2025Article
- NK cells in renal cell carcinoma and its implications for CAR-NK therapy.Frontiers in cell and developmental biology · 2025Review
- GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.Journal of cellular and molecular medicine · 2024Article
- Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment.The patient · 2024Article
- pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation.International journal of nanomedicine · 2024Article
- Article
- Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer.Journal of translational medicine · 2023Review
- Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022.Human vaccines & immunotherapeutics · 2023Article
- Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.BMC cancer · 2023Article
- Imidazolylpyrrolone-Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma.ChemMedChem · 2023Article
- Comprehensive analysis of lower mitochondrial complex I expression is associated with cell metastasis of clear cell renal cell carcinoma.Translational cancer research · 2022Article
- Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.Cureus · 2022Article
- Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis.Frontiers in immunology · 2022Article
- Expression of basement membrane genes and their prognostic significance in clear cell renal cell carcinoma patients.Frontiers in oncology · 2022Article
- NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation.International journal of biological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20-30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that-with the introduction of new drugs-the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.
Indexed as
Identifiers
30368624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.